strategic partnerships Archives - Medical Design Sourcing

Navigating the future of cell therapies with bit.bio exec Kathryn Corzo

Kathryn Corzo is currently the president and chief operating officer of bit.bio. The Cambridge, UK–based synthetic biology company specializes in providing human cells for research, drug discovery and cell therapy.

Her previous roles include a stint as the head of development for oncology cell therapies at Takeda. She also led the North American Innovation Center and R&D Digital Accelerator at Sanofi and held a leadership role in Lilly’s oncology business unit.

Bit.bio’s differentiated approach

Corzo’s decision to join bit.bio was rooted in the company’s pioneering approach to cell therapy. “Joining bit.bio became a clear choice,” she recalls. “The platform technology at bit.bio offers a solution to some of the significant challenges in the cell therapy field, mainly by manufacturing consistent cells at scale, speed and reduced costs thus democratizing access to human cells.…

Synthetica Bio lates to tap generative AI to spur drug discovery innovation

Interest in generative AI has skyrocketed in 2023. While the generative AI market is already substantial, worth $10 billion in 2022 according to Grand View Research, it is set to balloon by a compound annual growth rate (CAGR) of 35.6% from 2023 to 2030. It’s no wonder that a slew of companies — including Exscientia, Insilico Medicine, Atomwise and BenevolentAI — are eager to tap the technology to expedite drug discovery.

Enter Synthetica Bio

The latest entrant in the generative AI scene is Laguna Beach, California-based Synthetica Bio. The startup aims to explore generative AI and large language models (LLMs) to enable real-time data processing. The company, founded by Simon Arkell and Alex Dickinson, entrepreneurs with a successful track record in companies like the predictive analytics firm Predixion, digital pathology startup Deep Lens, biotech Helixis and the molecular diagnostics firm Chromacode, has formed strategic partnerships to propel its platform de…

Brain breakthroughs: Aprinoia Therapeutics’ harnesses AI and strategic partnerships to propel neurodegenerative disease research

Neurodegenerative disease research is witnessing significant advances. To that end, Hong Kong-headquartered Aprinoia Therapeutics is embracing a ‘precision neuroscience’ approach to neurodegeneration diagnostics. The company’s lead program, APN-1607, represents a new generation of advanced tau positron emission tomography (PET) tracers, which play a crucial role in effective and efficient diagnosis of patients suffering from neurodegenerative disorders.

Aprinoia Therapeutics’ strategy to neurodegenerative disease research focuses in part on artificial intelligence (AI) and forging strategic collaborations. Paul Tempest, the head of medicinal chemistry at Aprinoia, leads a team of experts in the field of neuroscience, AI, and pharmaceutical development. In a recent interview, Tempest explained how this multifaceted approach supports innovation in the development of novel diagnostic tools and therapies for neurodegenerative diseases.

AI in dr…